Journal of Clinical Pediatrics >
Macrolide resistance in hospitalized children with Mycoplasma pneumoniae pneumonia and its clinical diagnosis and treatment
Received date: 2024-01-10
Online published: 2024-03-06
Objective To summarize the epidemiological characteristics and drug resistance rate of Mycoplasma pneumoniae (MP) infection in hospitalized children from April to October 2023, and analyze the clinical and therapeutic characteristics of MPP children during this period. Methods Throat swab samples of children with community-acquired pneumonia were collected on the day of hospitalization. The tNGS pathogen and MP macrolide-resistance gene mutation were detected, and MP positive rate and MP macrolide-resistance rate were analyzed. Patients with MPP were grouped by the admission date into non-epidemic group (June) and epidemic group (September), and further divided into resistant group and sensitive group in accordance to whether the macrolide-resistance genes were positive or not. The clinical features of the children were compared among the groups. The treatment differences were discussed comparatively between the non-epidemic resistant group and the epidemic resistant group. Results The median age of 1425 children (686 boys and 739 girls) with community-acquired pneumonia was 6 (3-8) years, and the MP positive rate was 57.1% (813 cases). The positive rate of MP varied significantly from April to October for each month (P<0.001), and MP positive rate increased month by month (12.5%-71.6%). Among 813 hospitalized children with MPP, 627 were positive for macrolide-resistance gene mutation, and the total drug resistance rate of MP was 77.1%. The drug resistance rate of MP was 93.9% in the period of non-epidemic (April to June), and significantly decreased to 71.9% in the epidemic period (August to October). The drug resistance rate of MP varied significantly from April to October for each month (P<0.001). There were 76 children in the non-epidemic group and 189 in the epidemic group. Compared with the non-epidemic group, the length of hospital stay were longer and the levels of CRP and LDH were higher in the epidemic group, with statistical significance (P<0.05). There were 64 children in the sensitive group and 201 in the resistant group. Compared with the sensitive group, the hospital stay was longer and the LDH level was higher in the resistant group, and the difference was statistically significant (P<0.05). Of the 201 children with macrolide-resistant MPP, 71 were in the non-epidemic resistant group and 130 were in the epidemic resistant group. Compared with the non-epidemic resistant group, the time to defervescence after methylprednisolone was longer and the use rate of tetracycline antibiotics was higher in the epidemic resistant group, and the difference was statistically significant (P<0.05). Conclusions The epidemic period of MP is from August to October 2023. Compared with normal days, the infection rate of MP is higher during the epidemic period, but the macrolide-resistant rate of MP in hospitalized children is lower. MPP during this epidemic period triggered stronger immune response, displayed as longer hospital stay and higher inflammatory factor level. The possibility of a new prevalent strain should be considered. This prevalent strain was less sensitive to combine treatment of macrolide plus corticosteroids, and tetracycline drugs are needed to control infection.
Yutong GU , Fen YANG , Jianmin YE , Li HUA , Jing LI , Guodong DING . Macrolide resistance in hospitalized children with Mycoplasma pneumoniae pneumonia and its clinical diagnosis and treatment[J]. Journal of Clinical Pediatrics, 2024 , 42(3) : 182 -186 . DOI: 10.12372/jcp.2024.24e0025
[1] | 中华医学会儿科学分会呼吸学组,, 《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J]. 中华实用儿科临床杂志, 2015, 30(17): 1304-1308. |
[2] | 钱前, 季伟. 2006—2014年住院儿童呼吸道肺炎支原体感染的流行病学特征[J]. 重庆医学, 2016, 45(29): 4113-4116. |
[3] | Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016[J]. Epidemiol Infect, 2019, 147: e192. |
[4] | 于聪, 吕伟, 张晓英. MP 23S rRNA A2063G基因变异的社区获得性肺炎患儿临床表型与胸部影像的关系[J]. 临床儿科杂志, 2021, 39(4): 265-268. |
[5] | 黎燕, 钟礼立, 张兵, 等. 23S rRNA V区A2063G基因突变的肺炎支原体肺炎患儿临床特征分析[J]. 临床儿科杂志, 2018, 36(8): 569-574. |
[6] | Zhan XW, Deng LP, Wang ZY, et al. Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia[J]. Ital J Pediatr, 2022, 48(1): 190. |
[7] | Brown RJ, Nguipdop-Djomo P, Zhao H, et al. Mycoplasma pneumoniae epidemiology in England and Wales: a national perspective[J]. Front Microbiol, 2016, 7: 157. |
[8] | 胡亚美, 江载芳. 诸福棠实用儿科学[M]. 第8版. 北京: 人民卫生出版社, 2015: 1280-1282. |
[9] | 赵顺英, 钱素云, 陈志敏, 等. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 传染病信息, 2023, 36(4): 291-297. |
[10] | Beeton ML, Zhang XS, Uldum SA, et al. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016[J]. Euro Surveill, 2020, 25: 2-13. |
[11] | 王亚翠, 吴喜蓉, 刘芳, 等. 2016年至2019年北京住院儿童肺炎支原体感染流行病学特征和耐药性[J]. 中华实用儿临床杂志, 2022, 37(17): 1082-1085. |
[12] | 温超超, 卢燕鸣. 基于SAT技术分析浦江镇地区儿童肺炎支原体感染的流行病学特点[J]. 中华肺部疾病杂志(电子版), 2020, 13(4): 493-496. |
[13] | Lucier TS, Heitzman K, Liu SK, et al. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumonia[J]. Antimicrob Agents Chemother, 1995, 39(12): 2770-2773. |
[14] | Okazaki N, Narita M, Yamada S, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro[J]. Microbiol Immunol, 2001, 45(8): 617-620. |
[15] | 郑宝英, 闫超, 薛冠华, 等. 耐药肺炎支原体肺炎患儿的临床特点及流行基因型特征分析[J]. 中华实用儿科临床杂志, 2017, 32(10): 735-739. |
[16] | Zheng X, Lee S, Selvarangan R, et al. Macrolide-resistant Mycoplasma pneumoniae, United States[J]. Emerg Infect Dis, 2015, 21(8): 1470-1472. |
[17] | Tang M, Wang D, Tong X, et al. Comparison of different detection methods for Mycoplasma pneumoniae infection in children with community-acquired pneumonia[J]. BMC Pediatr, 2021, 21(1): 90. |
[18] | Xu C, Deng H, Zhang J, et al. Mutations in domain V of Mycoplasma pneumoniae 23S rRNA and clinical characteristics of pediatric M. pneumoniae pneumonia in Nanjing, China[J]. J Int Med Res, 2021, 49(6): 3000605211016376. |
[19] | 张伟利, 张新星, 顾文婧, 等. 肺炎支原体耐药在难治性肺炎支原体肺炎患儿发病中的作用[J]. 中华实用儿科临床杂志, 2021, 36(11) : 822-826. |
[20] | Nakamura Y, Oishi T, Kaneko K, et al. Recent acute reduction in macrolide-resistant Mycoplasma pneumoniae infections among Japanese children[J]. J Infect Chemother, 2021, 27(2): 271-276. |
[21] | Jiang TT, Sun L, Wang TY, et al. The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic[J]. Front Cell Infect Microbiol, 2023, 13: 1181402. |
[22] | 高龙飞, 张景丽, 吴晓杰, 等. IL-17A对于儿童难治性肺炎支原体肺炎预测作用[J]. 临床儿科杂志, 2023, 41(5): 366-369. |
[23] | 刘峰. 肺炎支原体肺炎与预后相关的临床指标[J]. 临床儿科杂志, 2022, 40(4): 247-251. |
[24] | 王崇杰, 骆学勤, 罗健, 等. 46例重症肺炎支原体肺炎合并胸腔积液患儿临床及预后分析[J]. 临床儿科杂志, 2020, 38(4): 269-274. |
[25] | 陈莉莉, 刘金荣, 赵顺英, 等. 常规剂量甲泼尼龙治疗无效的儿童难治性肺炎支原体肺炎的临床特征和治疗探讨[J]. 中华儿科杂志, 2014, 52(3): 172-176. |
[26] | Yang D, Chen L, Chen Z. The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings[J]. PLoS One, 2018, 13(1): e0191951. |
[27] | Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children[J]. Pediatr Pulmonol, 2014, 49(4): 377-380. |
/
〈 |
|
〉 |